Document is current
Any future updates will be listed below
-
Authors
Angelino, Elia https://orcid.org/0000-0002-4305-0863
Bodo, Lorenza
Sartori, Roberta
Malacarne, Valeria
D’Anna, Beatrice
Formaggio, Nicolò
Barua, Suvham
Raiteri, Tommaso
Lauria, Andrea https://orcid.org/0000-0003-4753-861X
Reano, Simone
Murabito, Alessandra
Nicolau, Monica https://orcid.org/0009-0004-6534-1874
Ferrero, Fabiana https://orcid.org/0009-0000-5097-6640
Pezzini, Camilla
Rossino, Giulia
Favero, Francesco
Valmasoni, Michele
Filigheddu, Nicoletta https://orcid.org/0000-0002-3848-611X
Menga, Alessio
Corà, Davide
Hirsch, Emilio
Oliviero, Salvatore https://orcid.org/0000-0002-3405-765X
Sartorelli, Vittorio
Proserpio, Valentina https://orcid.org/0000-0003-2071-4206
Ghigo, Alessandra https://orcid.org/0000-0002-1193-5296
Sandri, Marco https://orcid.org/0000-0001-8509-7558
Porporato, Paolo E. https://orcid.org/0000-0001-8519-1552
Talarico, Daniela
Caretti, Giuseppina https://orcid.org/0000-0002-2322-6008
Graziani, Andrea https://orcid.org/0000-0002-6302-2317
- License Information
-
More Information
Article History
Received: 11 June 2024
Accepted: 18 September 2025
First Online: 12 November 2025
Competing interests
: A. Ghigo and E.H. are co-founders and shareholders of Kither Biotech, a pharmaceutical company focused on the development of PI3K inhibitors for airway diseases that are not in conflict with the content of this manuscript. The other authors declare no competing interests.
